

Table 5. Efficacy

	ABLC (5 mg/kg/d) (n = 21)	CAB (n = 17)
Clinical response (success)	18 (86%)	11 (65%)
Mycological response (success)	8 (42%)	7 (50%)
Overall response (success)	8 (42%)	7 (50%)

Note: In regard to clinical response, 21 and 17 patients were assessed for each group. For mycological and overall response, only those patients who received more than 12 doses were used, which were 19 and 14 patients, respectively.